BPC-157 vs MK-2866 for recovery
Short answer: For recovery, users rate them about the same: 96% report improvement with BPC-157 (494 reports) and 96% with MK-2866 (78 reports).
BPC-157 has 0 meta-analyses and 0 randomized trials on PubMed; MK-2866 has 0 and 0.
Based on 1,613 reports about BPC-157 and 789 about MK-2866. Not medical advice.
| BPC-157 Peptide | MK-2866 SARM | |
|---|---|---|
| Users say it helped | 54%helped919 reports · high confidence | 37%helped489 reports · high confidence |
| Verdict | Mixed | Mixed |
| Research | DResearch: None | DResearch: None |
| Meta-analyses / RCTs | 0 / 0 | 0 / 0 |
| Mainly used for | ||
| Recovery % reporting improvement | 96% (494) | 96% (78) |
| Pain & inflammation % reporting improvement | 86% (485) | 71% (31) |
| Performance % reporting improvement | 95% (61) | 87% (252) |
| Mood % reporting improvement | 65% (128) | 66% (64) |
| Digestion % reporting improvement | 84% (111) | 0% (2) |
| Common side effects | fatigue, anhedonia, anxiety, headache | suppression, fatigue, insomnia, headache |
| Typical dose reported | Not listed | Not listed |
BPC-157Full BPC-157 profile →
What a user said
“after 2+ years of nothing working, this is the 1st thing to reverse significant muscle damage ... 40% increase in my range of motion, and nearly the same in muscle strength.”
MK-2866Full MK-2866 profile →
What a user said
“I've taken LDG-4033 and Ostarine from Ceretropic and noticed slight psychoactive effects from both, immediately (within 30 minutes after dosing).”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate